PLA2G7 and metabolic syndrome: In comparison to the control group, individuals in the MetS group exhibited significantly higher serum Lp-PLA2 levels (239.8 ± 45.6 ng/mL vs. 178.3 ± 30.2 ng/mL, p < 0.001).